Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Assenagon Asset Management S.A. trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 71.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,937 shares of the company’s stock after selling 158,767 shares during the period. Assenagon Asset Management S.A. owned about 0.16% of Keros Therapeutics worth $1,028,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. KBC Group NV lifted its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the third quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP purchased a new stake in Keros Therapeutics in the third quarter valued at approximately $213,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Trading Down 1.5 %

Shares of KROS stock opened at $11.84 on Friday. The firm has a fifty day simple moving average of $32.16 and a 200-day simple moving average of $46.27. The company has a market capitalization of $479.64 million, a PE ratio of -2.27 and a beta of 1.43. Keros Therapeutics, Inc. has a twelve month low of $9.77 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same period in the prior year, the firm posted ($1.33) earnings per share. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. Equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KROS. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright reduced their target price on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.